Prot #I4V-MC-JAHG(a): A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis

  • Silverberg, Jonathan I (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/11/16 → 2/11/19

Funding

  • Target Health Inc. (Prot #I4V-MC-JAHG(a) // Prot #I4V-MC-JAHG(a))
  • Lilly USA, LLC (Prot #I4V-MC-JAHG(a) // Prot #I4V-MC-JAHG(a))